Mesenchymal stem cells: a new trend for cell therapy
Mesenchymal stem cells (MSCs), the major stem cells for cell therapy, have been used in the clinic for approximately 10 years. From animal models to clinical trials, MSCs have afforded…
Diffuse and persistent blood–spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells
Intravenous infusion of mesenchymal stem cells (MSCs) has been shown to reduce the severity of experimental spinal cord injury (SCI), but mechanisms are not fully understood. One important consequence of…
Long-Term Follow-Up of Crohn Disease Fistulas After Local Injections of Bone Marrow–Derived Mesenchymal Stem Cells
Objective To assess the long-term outcome of patients treated with serial intrafistular injections of autologous bone marrow–derived mesenchymal stem cells (MSCs) for refractory Crohn fistulas in terms of safety and…
Epigallocatechin-3-gallate (EGCG) as a pro-osteogenic agent to enhance osteogenic differentiation of mesenchymal stem cells from human bone marrow: an in vitro study
The proliferation and osteogenic capacity of mesenchymal stem cells (MSCs) needs to be improved for their use in cell-based therapy for osteoporosis. (−)-Epigallocatechin-3-gallate (EGCG), one of the green tea catechins,…
- Go to the previous page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- …
- 537
- Go to the next page